miR-378a-5p improved the prognosis and suppressed the progression of hepatocellular carcinoma by targeting the VEGF pathway | Zendy

Haibo Zou | Zendy; LanYan Yang | Zendy

Open Access

miR-378a-5p improved the prognosis and suppressed the progression of hepatocellular carcinoma by targeting the VEGF pathway

Author(s) -

Haibo Zou,

LanYan Yang

Publication year - 2020

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2020.01.46

Subject(s) - hepatocellular carcinoma , cancer research , viability assay , flow cytometry , vascular endothelial growth factor , transfection , cell growth , downregulation and upregulation , cell culture , cell , microrna , biology , blot , medicine , immunology , vegf receptors , gene , biochemistry , genetics

Among malignant tumors, hepatocellular carcinoma (HCC) is the sixth most common in terms of occurrence and cancer-related death (1,2). Typically, HCC treatment involves surgery-based comprehensive therapies. However, the HCC prognosis remains poor, even following surgical resection, as there is a high frequency of recurrence and cancer cell migration into adjunct normal tissues (3,4). The 5-year postoperative recurrence rate of HCC is >60%, mainly due to recurrence and chemoresistance (5,6). Therefore, novel molecular mechanisms must be developed to treat tumor growth and migration. Micro-ribonucleic acids (miRNAs) are 19–22 nucleotides long and noncoding, and induce mRNA degradation by binding of the target mRNA 3’-untranslated region (UTR) or inhibiting translation (7). Studies have found Original Article

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research